Clinical Trial Update: Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating imatinib mesylate and sunitinib for gastrointestinal stromal tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)
• Sutent (sunitinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Gastrointestinal Stromal Tumor | Phase 1 | Status: TERMINATED